SeaSpine Holdings Corporation (SPNE) Bundle
A Brief History of SeaSpine Holdings Corporation (SPNE)
Corporate Formation and Initial Public Offering
SeaSpine Holdings Corporation was established in 2015, evolving from the merger of SeaSpine and SpineWave. The company's primary focus is on developing and marketing innovative spinal implant and orthobiologics solutions.
In September 2015, SeaSpine became a publicly traded company under the ticker symbol SPNE. The company’s IPO was priced at $13 per share, raising approximately $60 million in gross proceeds.
Product Development and Market Offerings
SeaSpine's product portfolio includes a range of spinal surgery solutions including:
- Spinal Implants: Devices used in fusion and stabilization surgeries.
- Orthobiologics: Products aimed at enhancing spine healing through biological materials.
- Navigation and Imaging Solutions: Technologies that assist in surgical procedures.
Financial Performance
In 2021, SeaSpine reported total revenues of $104.7 million, which represented a year-over-year increase of 12% compared to $93.5 million in 2020. The company achieved a gross profit of $65.1 million, yielding a gross margin of approximately 62.2%.
The following table summarizes SeaSpine's financial performance over recent years:
| Fiscal Year | Total Revenue ($ million) | Gross Profit ($ million) | Gross Margin (%) |
|---|---|---|---|
| 2019 | 82.8 | 50.5 | 61.0 |
| 2020 | 93.5 | 56.1 | 60.0 |
| 2021 | 104.7 | 65.1 | 62.2 |
| 2022 | 113.0 (estimated) | 70.0 (estimated) | 61.9 (estimated) |
Strategic Acquisitions
In 2020, SeaSpine acquired Zyga Technology, Inc., a company known for its surgical devices for treating degenerative conditions of the spine, bolstering its product lineup. The acquisition was valued at around $25 million.
In 2021, SeaSpine further enhanced its portfolio through the acquisition of Surgalign Holdings, expanding its capabilities in digital surgery.
Market Position and Competitive Landscape
As of 2021, SeaSpine held approximately 1.6% of the U.S. spinal implant market, which is estimated to be valued at around $11 billion. The company competes with major players such as Medtronic, Zimmer Biomet, and DePuy Synthes.
Recent Developments and Innovations
SeaSpine continues to innovate with its latest product release, the Voyant™ System, which is aimed at enhancing the surgical experience and improving patient outcomes. The launch of this system was noted in Q2 2021 and has contributed to revenue growth in subsequent quarters.
Stock Performance and Investor Information
As of October 2023, SeaSpine's stock price hovered around $12.50, reflecting a 15% increase from the previous year. The company has a market capitalization of approximately $400 million.
The stock has shown a 52-week range between $9.00 and $15.00. The company reported around 18 million shares outstanding.
A Who Owns SeaSpine Holdings Corporation (SPNE)
Shareholder Composition
As of the latest filing period, the ownership of SeaSpine Holdings Corporation (SPNE) comprises various institutional and retail shareholders. The overall shareholder structure can be outlined as follows:
| Shareholder Type | Percentage of Ownership | Number of Shares |
|---|---|---|
| Institutional Investors | 61.2% | 10,305,000 |
| Insider Ownership | 5.0% | 840,000 |
| Retail Investors | 33.8% | 5,650,000 |
Major Institutional Shareholders
The largest institutional shareholders of SeaSpine Holdings include:
| Institution | Shares Held | Percentage of Total Shares |
|---|---|---|
| BlackRock, Inc. | 1,200,000 | 7.2% |
| Vanguard Group, Inc. | 950,000 | 5.8% |
| Dimensional Fund Advisors | 850,000 | 5.1% |
| Wellington Management Company | 700,000 | 4.2% |
Insider Ownership
Insider ownership plays a pivotal role in the governance of SeaSpine Holdings. Key insiders include:
| Insider Name | Position | Shares Owned |
|---|---|---|
| Jason A. Reilly | CEO | 350,000 |
| Keith M. Dorr | CFO | 200,000 |
| Mark J. Heller | COO | 150,000 |
Recent Stock Performance
As of October 2023, SeaSpine Holdings' stock (SPNE) has shown significant activity in the market:
| Metric | Value |
|---|---|
| Current Stock Price | $8.25 |
| Market Capitalization | $215 million |
| 52-Week High | $12.00 |
| 52-Week Low | $6.75 |
Recent Changes in Ownership
Recent changes in the ownership structure of SeaSpine Holdings include:
- Increased investment by BlackRock, Inc. by 150,000 shares.
- Vanguard Group, Inc. reduced its stake by 50,000 shares.
- New institutional investors acquiring around 300,000 shares collectively in Q3 2023.
Conclusion
Understanding the ownership structure of SeaSpine Holdings Corporation is crucial for analyzing its financial health and governance policies. The mix of institutional and insider holdings reflects a diverse ownership that impacts corporate decisions and strategic direction.
SeaSpine Holdings Corporation (SPNE) Mission Statement
Corporate Overview
SeaSpine Holdings Corporation is a global medical technology company specializing in spinal surgery solutions. The company's mission is to be a leader in the transformation of spinal surgery through innovation and offering comprehensive solutions that address the needs of healthcare professionals and patients.
Mission Statement
SeaSpine’s mission statement reflects its commitment to delivering exceptional products and services that enhance spinal surgery outcomes. Specifically, it emphasizes:
- Innovation in spinal technologies.
- Focus on patient safety and surgical efficiency.
- Partnership with healthcare professionals.
- Commitment to continuous improvement and education in spinal care.
Financial Performance
As of the fiscal year ending December 31, 2022, SeaSpine reported:
| Metric | Amount (USD) |
|---|---|
| Total Revenue | $92.4 million |
| Net Loss | ($15.5 million) |
| Gross Margin | 57% |
| Operating Expenses | $56.9 million |
Product Offering
SeaSpine's product portfolio includes:
- Spinal implants and devices.
- Biologics and spinal imaging technologies.
- Minimally invasive surgical solutions.
Market Position
In the spinal surgery market, SeaSpine holds a significant position with a market share of approximately 2.5% as of 2023. The overall spinal implant market is projected to grow at a CAGR of 3.8%, reaching $16.6 billion by 2025.
Research and Development Investment
For the year 2022, SeaSpine allocated $7.2 million to research and development, which represents approximately 7.8% of its total revenue. The focus areas include:
- Advanced spinal fusion solutions.
- Biomechanics and materials science.
- Digital surgical planning tools.
Partnerships and Collaborations
SeaSpine actively collaborates with key institutions and surgeons to enhance its offerings. Current partnerships include:
- Major academic medical centers for clinical trials.
- Surgeon advisory boards for product feedback.
Stock Performance
As of October 2023, SeaSpine’s stock price is approximately $8.50 per share, with a market capitalization of about $350 million. The company’s stock has seen a year-to-date increase of 25%.
Commitment to Sustainability
SeaSpine is dedicated to sustainable practices, aiming to reduce waste by 30% by 2025. It has initiated programs to improve energy efficiency across its manufacturing processes.
Conclusion on Mission Alignment
SeaSpine's operational strategies and financial performance align closely with its mission statement, demonstrating a commitment to innovation, quality, and sustainability in spinal surgery technologies.
How SeaSpine Holdings Corporation (SPNE) Works
Company Overview
SeaSpine Holdings Corporation (SPNE) is focused on developing and distributing innovative surgical solutions for the treatment of spinal disorders. The company is headquartered in Carlsbad, California, and operates within the medical technology industry.
Product Categories
SeaSpine’s product portfolio is divided into several key categories:
- Spinal Implants
- Orthobiologics
- Surgical Instruments
Financial Performance
As of Q3 2023, the financial performance of SeaSpine is as follows:
| Metric | Q3 2023 (in millions) |
|---|---|
| Revenue | $36.7 |
| Gross Profit | $25.1 |
| Operating Income | -$3.0 |
| Net Loss | -$4.5 |
| Cash and Cash Equivalents | $45.2 |
Market Strategy
SeaSpine employs a multi-faceted market strategy that includes:
- Direct Sales Force
- Strategic Partnerships
- Targeting Key Surgical Centers
Research and Development
In 2022, SeaSpine invested approximately $8.2 million in Research and Development, focusing mainly on improving spinal fusion technologies and enhancing surgical workflows.
Distribution Channels
SeaSpine utilizes a variety of distribution channels, including:
- Direct sales through internal sales representatives
- Independent distributors
- Online platforms for educational resources and product information
Competitive Landscape
SeaSpine operates in a competitive landscape consisting of major players such as:
- Medtronic
- DePuy Synthes
- Stryker
Recent Developments
As of October 2023, SeaSpine announced a new partnership with a leading research institution to advance its orthobiologics product line, aiming to enhance regeneration technologies used in spinal surgeries.
Market Trends
The spinal surgery market is projected to reach $13 billion by 2026, with a CAGR of 6.2%. SeaSpine's growth is supported by increasing aging populations and technological advancements in spinal procedures.
Conclusion on Operations and Financials
As of Q3 2023, SeaSpine reported an increase in revenue by 15% year-over-year, reflecting a growing demand for innovative spinal solutions and successful market penetration strategies.
How SeaSpine Holdings Corporation (SPNE) Makes Money
Product Lines
Product Lines
SeaSpine Holdings Corporation generates revenue through a diversified portfolio of spinal implant products and biologics. As of 2023, the company offers over 300 distinct products in two primary categories: spinal hardware and biologics.
Spinal Hardware Sales
In the fiscal year 2022, spinal hardware represented approximately $85 million of SeaSpine's total revenue, which accounted for about 70% of overall sales. The hardware segment includes:
- Pedicle screws
- Interbody devices
- Spinal fusion products
The average selling price (ASP) for spinal hardware is around $2,500 per unit.
Biologics Sales
The biologics segment accounted for around $36 million, approximately 30% of the total revenue in 2022. The key products in the biologics category include:
- Bone graft substitutes
- Demineralized bone matrix
- Growth factors
The average price for biologics products is estimated at $1,200 per unit.
Geographic Distribution of Revenue
In terms of geographic revenue streams, the company reported the following distribution in 2022:
| Region | Revenue ($ millions) | Percentage of Total Revenue (%) |
|---|---|---|
| United States | 97 | 80 |
| International | 24 | 20 |
Research and Development (R&D)
SeaSpine invests significantly in R&D to innovate and expand its product offerings. In 2022, R&D expenditures were approximately $15 million, which is crucial for maintaining competitiveness in the spinal surgery market.
Market Demand & Growth
The global spinal implant market was valued at roughly $12 billion in 2021 and is projected to grow at a CAGR of 4.3% through 2028. This growth is driven by factors such as an aging population and increasing incidences of spinal disorders.
Strategic Partnerships
SeaSpine has established key partnerships and collaborations, contributing to its revenue stream through licensing agreements and joint ventures. These arrangements have provided additional revenue sources of approximately $5 million in 2022.
Financial Performance Metrics
During 2022, SeaSpine reported the following financial metrics:
| Metric | Amount |
|---|---|
| Total Revenue | $121 million |
| Net Income (Loss) | ($12 million) |
| Gross Margin | 45% |
| EBITDA | ($8 million) |
Sales and Distribution Channels
SeaSpine utilizes a multi-channel sales strategy that includes direct sales force and third-party distributors. The company employs over 100 sales representatives across the U.S., contributing to broader market penetration and customer relationships.
SeaSpine Holdings Corporation (SPNE) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support